Skip to main content

Fiscal Wizard · Single-issue tearsheet

OMER / Jun 21, 2026 Run #7362

OMER

Omeros Corporation

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; OncotoX-AML, to treat acute myeloid leukemia; and Targeted Complement Activating Therapy, for Multidrug-resistant organisms. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

Composite verdict

B 61.0 / 100
Gated stand-aside 0 drivers · 5 gates blocking
Stand aside Setup or conviction grade does not support a directional trade.

Industry rank 46th of 598 in Biotechnology

rescore-sweep
Technical synthesisRegime: uptrend

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes from

Earnings power doesn't cover the capital structure (high debt) — the EPV decomposition isn't meaningful for this name.

Fundamentals Above average

61.0 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
Cash Conversion Cycle 100
Free Cash Flow Yield 0
EPS Growth (YoY) 100
Inventory Turnover 0
Revenue Growth (YoY) 100
P/S Ratio 25

Technicals Unscored

/ 100

Stand aside — active guards gated the directional signals that fired. · 43 signals shown.

Risk Gates

5 blocking 7 caution

5 guards active, 43 signals gated.

Altman Z-Score Blocking

Bottom-band Altman Z blocks bullish signals — distress risk.

Beneish M-Score Blocking

Bottom-band Beneish M blocks bullish signals — accounting-quality risk.

Interest Coverage Blocking

Weak interest coverage blocks bullish signals — debt-service risk.

Realized Volatility Regime Blocking

High-vol regime mutes mean-reversion signals; low-vol regime mutes breakout signals.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for OMER.